commences ind application for cvac

Sydney - Tuesday - April 28: (RWE Aust Business News) - Prima
BioMed Ltd (ASX:PRR) has now commenced its Investigational New Drug (IND)
application with the US Food and Drug Administration (FDA) for the CVac
ovarian cancer treatment.
The granting of Investigational New Drug status is a
pre-requisite for all new drug applications seeking FDA approval to
licence a drug for commercial use.
In the coming weeks Prima will offer the opportunity for eligible
shareholders to subscribe for new shares in Prima BioMed through a
further Share Purchase Plan (SPP).
It is proposed that under the SPP, eligible shareholders will be
able to subscribe for up to $5,000 in new ordinary shares in Prima and
the monies raised will be used to help Prima fund its upcoming
US FDA pivotal trial.
Shareholders who were issued shares in Prima under the previous
SPP in December 2008 will be limited from investing further funds under
the new SPP to the extent that to do so would result in the aggregate
amount invested by that shareholder exceeding $5,000.